Literature DB >> 17437488

The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive skin neoplasms.

Melanie Neumann1, Erik Dülsner, Gerhard Fürstenberger, Karin Müller-Decker.   

Abstract

Prostaglandin (PG) E(2), the predominant PG in skin, accumulates in experimentally produced mouse skin tumors. PGE(2) induces proliferation of mouse keratinocytes in vitro, epidermal hyperplasia and dysplasia, a promoted epidermis phenotype, and angiogenesis in keratin 5 promoter (K5) cyclooxygenase (COX)-2-transgenic NMRI mouse skin in vivo. PGE(2) is synthesized by COX-catalysed oxygenation of arachidonic acid to PGH(2) and its conversion to PGE(2) by prostaglandin E synthase (PGES) isoforms. PGE(2) signals via PGE(2) receptor isoforms EP1-EP4. Here, we investigated the expression profiles of PGES and EP receptors in wild type NMRI mouse skin constitutively expressing COX-1 when compared with the hyperplastic/dysplastic skin of homozygous K5 COX-2-transgenic mice and papillomas of both genotypes, which, in addition to COX-1, overexpress COX-2. The three PGES are constitutively expressed in normal and transgenic skin independent of the COX expression status. In papillomas, the increased PGE(2) levels correlate with an increased expression of mPGES-1 and cPGES. All four EP receptors were expressed in normal and transgenic skin. Only EP3 was slightly increased in transgenic skin. In papillomas of both genotypes, the expression levels of EP1 and EP4 were low when compared with those in wild type back skin. EP2 was the predominant receptor in papillomas of wild type and transgenic mice. In papillomas of wild type mice EP3 levels were slightly elevated when compared with transgenic tumors. EP1 and EP2 were localized in basal keratinocytes, sebaceous glands and CD31-positive vessels. Thus, normal and preinvasive mouse skin express the complete protein repertoire for PGE(2) biosynthesis and signalling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437488     DOI: 10.1111/j.1600-0625.2007.00549.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  6 in total

1.  The EP1 subtype of prostaglandin E2 receptor: role in keratinocyte differentiation and expression in non-melanoma skin cancer.

Authors:  R L Konger; S D Billings; N C Prall; T M Katona; S C Dasilva; C R J Kennedy; S Badve; S M Perkins; P T Lacelle
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-07-22       Impact factor: 4.006

2.  The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.

Authors:  Melissa S Simper; Joyce E Rundhaug; Carol Mikulec; Rebecca Bowen; Jianjun Shen; Yue Lu; Kevin Lin; Inok Surh; Susan M Fischer
Journal:  Mol Oncol       Date:  2014-07-03       Impact factor: 6.603

3.  Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.

Authors:  John A Taylor; Benjamin Ristau; Mathilde Bonnemaison; Olga S Voznesensky; Poornima Hegde; George A Kuchel; Carol C Pilbeam
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-09-12       Impact factor: 3.072

Review 4.  The role of the EP receptors for prostaglandin E2 in skin and skin cancer.

Authors:  J E Rundhaug; M S Simper; I Surh; S M Fischer
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Expression pattern of cyclooxygenase-2 in normal rat epidermis and pilosebaceous unit during hair cycle.

Authors:  Yuanxu Xu; Li Yang; Tian Yang; Mingming Xiang; Enyi Huang; Xiaohua Lian
Journal:  Acta Histochem Cytochem       Date:  2008-10-28       Impact factor: 1.938

6.  Preventive effect of Dioscorea japonica on squamous cell carcinoma of mouse skin involving down-regulation of prostaglandin E2 synthetic pathway.

Authors:  Izumi Tsukayama; Keisuke Toda; Yasunori Takeda; Takuto Mega; Mitsuki Tanaka; Yuki Kawakami; Yoshitaka Takahashi; Masumi Kimoto; Kei Yamamoto; Yoshimi Miki; Makoto Murakami; Toshiko Suzuki-Yamamoto
Journal:  J Clin Biochem Nutr       Date:  2018-01-12       Impact factor: 3.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.